Is a complete TARS research report available?

No complete published report is available for Tarsus Pharmaceuticals, Inc. (TARS) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Tarsus Pharmaceuticals, Inc. (TARS)

NASDAQ: TARS · USD

$58.5

-0.43 (-0.7%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-30 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first TARS analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	2.5B
Revenue (ttm)	535.1M
Net income (ttm)	-48.3M
EPS (ttm)	-$1.13
Shares out	43M
Volume	679,776
Beta	0.50
Price target	$94.4	+61.4%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 535.1M
Net income (ttm): -48.3M
EPS (ttm): -$1.13
Market cap: 2.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All TARS indicators

Market & fundamental data

Available fields

214

Groups with data

Currency

USD

Showing 214 of 214 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001819790
Company name	Tarsus Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	87650L103
Employees	370
Employees Change	47%
Employees Change Percent	14.55
Enterprise value	$2.2B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-10-16
Isin	US87650L1035
Last refreshed	2026-07-30
Market cap	$2.5B
Market cap category	Mid-Cap
Price	$58.52
Price currency	USD
Rev Per Employee	1,446,159.46x
Sector	Healthcare
Sector PE	45.64
Sector PE Fwd	24.21
Sic	2836
Symbol	TARS
Website	https://tarsusrx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-1.92%
EV Sales Forward	3x
EV/Sales	4.14x
FCF yield	-1.25%
P/B ratio	7.21x
P/S ratio	4.71x
PS Forward	3.41x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-9.5%
EBITDA Margin	-9.16%
Gross margin	79.98%
Gross Profit	$427.9M
Gross Profit Growth	164.88%
Gross Profit Growth Q	121.93%
Net Income	$-48.3M
Net Income Growth Quarters	7%
Net Income Growth Years	2%
Pretax Margin	-8.2%
Profit Margin	-9.02%
Profit Per Employee	$-130,446
ROA	-5.87
Roa5y	-18.56
ROCE	-11.61
ROE	-13.96
Roe5y	-38.15
ROIC	-7.45

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	40.2%
Cagr3y	36.69%
Cagr5y	19.84%
EPS Growth Quarters	8
EPS Growth Years	2
Revenue Growth	128.99x
Revenue Growth Q	106.87x
Revenue Growth Quarters	7x
Revenue Growth Years	2x
Revenue Growth3 Y	168.07x
Revenue Growth5 Y	74.12x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.99
Assets	$581.1M
Cash	$388.7M
Current Assets	$537.2M
Current Liabilities	$143.5M
Debt	$88.7M
Debt Equity	$0.25
Equity	$349M
Interest Coverage	-5.74
Liabilities	$232.2M
Long Term Assets	$43.9M
Long Term Liabilities	$88.7M
Net Cash	$300.1M
Net Cash By Market Cap	$11.92
Net Cash Growth	-10.58%
Net Debt Equity	$-0.86
Tangible Book Value	$341.8M
Tangible Book Value Per Share	$7.95
WACC	7.02

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.74
Inventory Turnover	29.44
Net Working Capital	$5M
Quick ratio	3.53
Working Capital	$393.7M
Working Capital Turnover	$1.36

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-10.54%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	40.17%
200-day SMA	68.78
3Y total return	155.43%
50-day SMA	61.27
50-day SMA vs 200-day SMA	50under200
5Y total return	147.13%
All Time High	85.25
All Time High Change	-31.35%
All Time High Date	2025-12-09
All Time Low	10.8
All Time Low Change	441.85%
All Time Low Date	2022-05-09
ATR	3.2
Beta	0.5
Beta1y	0.14
Beta2y	0.09
Ch YTD	-28.53
High	59.4
High52	85.25
High52 Date	2025-12-09
High52ch	-31.35%
Low	57.33
Low52	38.51
Low52 Date	2025-08-01
Low52ch	51.96%
Ma50ch	-4.49%
Price vs 200-day SMA	-14.91%
RSI	45.76
RSI Monthly	52.91
RSI Weekly	42.92
Sharpe ratio	0.87x
Sortino ratio	1.55
Total Return	-10.54%
Tr YTD	-28.53
Tr1m	-6.99%
Tr1w	1.63%
Tr3m	-5.75%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	9
Analyst Count Top	5
Analyst Price Target Top	$92.8
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.25
Earnings Revenue Estimate	167,224,200x
Earnings Revenue Estimate Growth	62.89x
Operating Income	$-50.8M
Operating margin	-9.5
Price target	$94.44
Price Target Change	$61.38
Price Target Change Top	$58.58

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	32,112,117%
Float Percent	74.64%
Shares Insiders	3.26%
Shares Institutions	86.78%
Shares Out	43,023,959
Shares Qo Q	0.4%
Shares Yo Y	10.54%
Short Float	18.01%
Short Ratio	4.26
Short Shares	13.44

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-78.3M
Adjusted OCF	-63,209,000
Average Volume	1,337,588.1x
Bv Per Share	8.11
CAPEX	$-15.1M
Ch1m	-6.99
Ch1w	1.63
Ch1y	40.17
Ch3m	-5.75
Ch3y	155.4
Ch5y	147.1
Ch6m	-8.82
Change	-0.73%
Change From Open	-0.41
Close	58.95
Days Gap	-0.32
Depreciation Amortization	1,793,000
Dollar Volume	39,780,491.5
Earnings Date	2026-08-05
Earnings Time	amc
EBIT	$-50.8M
EBITDA	$-49M
EPS	$-1.13
F Score	3
FCF	$-31.5M
FCF EV Yield	-1.42x
FCF Per Share	$-0.73
Financing CF	8,030,000
Fiscal Year End	December
Founded	2,016
Income Tax	$4.4M
Investing CF	-65,735,000
Ipr	265.8
Iprfo	261.2
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-23
Ma150	66.72
Ma150ch	-12.29%
Ma20	60.52
Ma20ch	-3.3%
Net CF	-74,157,000
Next Earnings Date	2026-08-10
Open	58.76
Optionable	Yes
Position In Range	57.49
Post Close	58.52
Postmarket Change Percent	-0.89
Postmarket Price	$58
Ppne	27,666,000
Price Date	2026-07-29
Ptbv Ratio	7.37
Relative Volume	0.51x
Revenue	535,079,000x
SBC By Revenue	8.74x
Share Based Comp	46,757,000
Tax By Revenue	0.82x
Tr6m	-8.82%
Us State	California
Volume	679,776
Z Score	6.92

Tarsus Pharmaceuticals, Inc. (TARS)

Coverage state: Market snapshot only — no published research

Generate the first TARS analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · TARS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TARS indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on TARS

Frequently asked questions